Brief: Pulmatrix And Cipla Announce First Patient Dosed In Phase 2 Trial Evaluating Pulmazole
18/09/2019 16:11
Sept 18 (Reuters) - Pulmatrix Inc PULM.O :
* PULMATRIX AND CIPLA ANNOUNCE FIRST PATIENT DOSED IN PHASE
2
TRIAL EVALUATING PULMAZOLE FOR TREATMENT OF ALLERGIC
BRONCHOPULMONARY ASPERGILLOSIS IN PATIENTS WITH ASTHMA
* PULMATRIX INC - STUDY TO SUPPORT PROOF-OF-CONCEPT
MECHANISM WITH
TOP LINE DATA EXPECTED MID-2020
Source text for Eikon: urn:newsml:reuters.com:*:nPn7Z7QxJa
Further company coverage: PULM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulmatrix
See all newsBrief: Pulmatrix Announces Second Quarter 2026 Financial Results And Progress On Merger
Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM